<DOC>
	<DOCNO>NCT02516527</DOCNO>
	<brief_summary>The purpose study determine whether ipilimumab effective treatment select advance ( unresectable , metastatic , recurrent ) solid tumor Chinese subject .</brief_summary>
	<brief_title>A Phase 1 Dose Escalation Study Safety , Tolerability , Pharmacokinetics Ipilimumab Chinese Subjects With Select Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Subjects follow advanced solid tumor ; metastatic recurrent Must measurable/nonmeasurable lesion per Response Evaluation Criteria Solid Tumors ( RECIST v1.1 ) criterion . Subjects ability comply treatment , procedure pharmacokinetics ( PK ) sample collection require study followup Chinese woman men , age 18 year old Subjects brain metastasis exclude unless clinically stable 4 week time randomization determine investigator Subjects ocular melanoma exclude Any malignancy subject free disease less two year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix History , currently active , autoimmune disease , include limited inflammatory bowel disease , rheumatoid arthritis , autoimmune hepatitis , systemic sclerosis ( scleroderma variant ) , systemic lupus erythematosus , autoimmune vasculitis , autoimmune neuropathy ( eg , GuillainBarre syndrome ) . Vitiligo exclude Any current history immunodeficiency , splenectomy , splenic radiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>